Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
“This study represents a major step forward in how we respond to cardiac arrest in the United States,” explained Monique Starks, MD, principal investigator. “By integrating drone technology into emergency care, we’re working to close the critical gap between cardiac arrest and treatment."
Palliative care is a recommended part of heart failure management in the U.S., but consultation rates remain low. The trend appears to impact Black patients more than other races and ethnicities.
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.
The Acurate neo2 TAVR valve has been used to treat severe aortic stenosis in other parts of the world for years. In the United States, however, the device has still not been approved for commercial use.
Treating AMI patients with colchicine is not associated with better cardiovascular outcomes, according to new data presented at TCT. The drug did help with inflammation, but that was the only benefit researchers could identify.
